-+ 0.00%
-+ 0.00%
-+ 0.00%
Gibel announced that the company recently received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the application for marketing of tergixetine hydrobromide, a new drug under development, has been accepted. This drug is a new antidepressant with a novel multi-receptor mechanism of action, and has good safety and tolerability. Currently, the marketing application for the relevant formulation is in progress. There are uncertainties such as the long cycle and number of steps in the development of new drugs. The company will promptly fulfill its information disclosure obligations in the future.
Share
Listen to the news
Gibel announced that the company recently received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the application for marketing of tergixetine hydrobromide, a new drug under development, has been accepted. This drug is a new antidepressant with a novel multi-receptor mechanism of action, and has good safety and tolerability. Currently, the marketing application for the relevant formulation is in progress. There are uncertainties such as the long cycle and number of steps in the development of new drugs. The company will promptly fulfill its information disclosure obligations in the future.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending